Cargando…

182P Impact of SARS CoV 2 outbreak in the molecular diagnosis of advanced NSCLC: A retrospective comparative cohort study

Detalles Bibliográficos
Autores principales:	Marin, E., Teixido, C., Arcocha, A., Castillo, S., Reyes, R., Viñolas, N., Mezquita, L., Muñoz, S., Martinez, D., Jares, P., Reguart, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Association for the Study of Lung Cancer. Published by Elsevier Inc. Published by Elsevier Inc. 2021
Materias:	Advanced Nsclc
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997780/ http://dx.doi.org/10.1016/S1556-0864(21)02024-4

Ejemplares similares

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19
por: Cui, W., et al.
Publicado: (2021)

179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center
por: Pierre, C., et al.
Publicado: (2021)

Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients
por: Marin, Elba, et al.
Publicado: (2020)

A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC
por: Aya, Francisco, et al.
Publicado: (2021)

Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients
por: Marin, Elba, et al.
Publicado: (2020)

Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
por: González de Aledo-Castillo, José Manuel, et al.
Publicado: (2021)

Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice
por: González de Aledo-Castillo, José Manuel, et al.
Publicado: (2021)

The Peninsula stage III non-small cell lung cancer audit: assessing the impact of COVID-19 on treatment decisions
por: Smith, Philippa, et al.
Publicado: (2023)

Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review
por: Tjong, Michael C., et al.
Publicado: (2021)

EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non–Small Cell Lung Cancer
por: Martin-Deleon, Roberto, et al.
Publicado: (2021)

Crizotinib治疗ALK阳性伴骨髓转移的肺腺癌1例及文献复习
Publicado: (2015)

EML4-ALK融合基因阳性肺腺癌合并淋巴瘤1例并文献复习
Publicado: (2015)

非小细胞肺癌患者EML4-ALK融合基因突变研究
Publicado: (2015)

ALK阳性非小细胞肺癌患者克唑替尼耐药的机制和治疗措施
Publicado: (2015)

初露端倪——演绎ALK阳性非小细胞肺癌的中国故事
Publicado: (2015)

增强免疫组化和原位杂交方法检测非小细胞肺癌的ALK重排的临床可行性
Publicado: (2015)

ALK阳性非小细胞肺癌的诊断
Publicado: (2015)

Stage and tissue-specific prognostic impact of miR-182 in NSCLC
por: Stenvold, Helge, et al.
Publicado: (2014)

MA03.08 Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer
por: Reyes, R., et al.
Publicado: (2021)

P09.15 Severity of Lung Cancer Disease in Hospitalized Patients During COVID-19
por: Fernández-Mañas, L., et al.
Publicado: (2021)

PD-L1 expression testing in non-small cell lung cancer
por: Teixidó, Cristina, et al.
Publicado: (2018)

Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
por: Toledo-Romani, María Eugenia, et al.
Publicado: (2022)

P09.28 Access to Intermediate and Intensive Care for Patients With Lung Cancer During the COVID-19 Period
por: Gorría, T., et al.
Publicado: (2021)

Group testing performance evaluation for SARS-CoV-2 massive scale screening and testing
por: Nalbantoglu, Ozkan Ufuk
Publicado: (2020)

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
por: Russo, Alessandro, et al.
Publicado: (2020)

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021)

Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection
por: Natarajan, Aravind, et al.
Publicado: (2022)

Qualitative monitoring of SARS-CoV-2 mRNA vaccination in humans using droplet microfluidics
por: Broketa, Matteo, et al.
Publicado: (2023)

in silico Surveillance: evaluating outbreak detection with simulation models
por: Lewis, Bryan, et al.
Publicado: (2013)

Simultaneous detection and mutation surveillance of SARS-CoV-2 and multiple respiratory viruses by rapid field-deployable sequencing
por: Bi, Chongwei, et al.
Publicado: (2021)

Sample-to-Answer and Routine Real-Time RT-PCR: A Comparison of Different Platforms for SARS-CoV-2 Detection
por: Wen, Donghua, et al.
Publicado: (2021)

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
por: Puranik, Arjun, et al.
Publicado: (2022)

Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation
por: Zhang, Tianxiang, et al.
Publicado: (2021)

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors
por: Zeng, Cong, et al.
Publicado: (2020)

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
por: Xia, Bing, et al.
Publicado: (2020)

Alternative graphical displays for the monitoring of epidemic outbreaks, with application to COVID-19 mortality
por: Perneger, Thomas, et al.
Publicado: (2020)

Comments on ‘An airway organoid-based screen identifies a role for the HIF1α‒glycolysis axis in SARS-CoV-2 infection’
por: Duan, Xiaohua, et al.
Publicado: (2021)

Highly susceptible SARS-CoV-2 model in CAG promoter–driven hACE2-transgenic mice
por: Asaka, Masamitsu N., et al.
Publicado: (2021)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020)

HIV infection drives interferon signaling within intestinal SARS-CoV-2 target cells
por: Fardoos, Rabiah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1mghdh1hq2lrtlsphm3qaqcepa